Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance
July 29, 2015 4:04 PM EDTNEWARK, Calif., July 29, 2015 /PRNewswire/ --Â Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended June 30, 2015.
"Depomed has rapidly become a leading force in the pain and neurology marketplace, with significant net product revenue growth that positions us to continue to deliver substantial value to our shareholders in both the immediate and long term," said Jim Schoeneck, President and CEO of Depomed. "Growth in the second quarter was led by our flagship product NUCYNTA, which had a strong performance in the first... More
Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
July 29, 2015 4:03 PM EDTNEWARK, Calif., July 29, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that its Board of Directors, after careful consideration and with the assistance of its independent financial and legal advisors, has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon") to acquire all of the outstanding shares of Depomed in an all-stock transaction (the "July 21 Proposal").
The Depomed Board concluded that the July 21 Proposal is inadequate and not in the best interests of... More
Depomed to Report Second Quarter Fiscal Year 2015 Financial Results on Wednesday, July 29, 2015
July 29, 2015 8:00 AM EDT
NEWARK, Calif., July 29, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2015 financial results after the close of market today, Wednesday, July 29, 2015. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international).... More
